Last reviewed · How we verify
NCT02728817: RADAR
Evaluation of the Radial Artery Deviation And Reimplantation Technique for Primary Hemodialysis Access Creation
NA trial testing End-cephalic vein to side-radial artery fistula creation in End-stage Renal Disease in 200 participants. Participants enrolled and being followed up; not accepting new ones.
12 April 2018
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Nice |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 12 April 2017 |
| Primary completion | 12 April 2018 |
| Estimated completion | 9 September 2026 |
| Sites | 4 locations across France |
Drugs / interventions tested
- End-cephalic vein to side-radial artery fistula creation
- RADAR fistula creation
Conditions studied
- End-stage Renal Disease — all drugs for End-stage Renal Disease →
Sponsor
Centre Hospitalier Universitaire de Nice
Who can join
18 and older, any sex, with End-stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Radial Artery Deviation And Reimplantation (RADAR) technique is a new approach for the construction of hemodialysis arteriovenous fistula. In this technique, the radial artery pedicle is deviated towards the minimally dissected cephalic vein at the wrist. The aim of this study is to compare the safety and efficacy of this technique with the traditional end-cephalic to side-radial arteriovenous fistula, currently used as a first line vascular access in hemodialysis patients. The hypothesis is that the minimal dissection concept used in the RADAR inhibits venous juxta-anastomotic neointimal hyperplasia and stenosis, and lead to higher rates of maturation and patency.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Artery to vein configuration of arteriovenous fistula improves hemodynamics to increase maturation and patency.
Bai H, Sadaghianloo N, Gorecka J, Liu S, et al · · 2020 · cited 33× · PMID 32817365 · DOI 10.1126/scitranslmed.aax7613
Verify or expand the search:
- PubMed search for NCT02728817
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End-stage Renal Disease
Currently open trials in the same condition.
- NCT06755372 — The Role of Toll-like Receptor-4 in Periodontitis Patients With End-stage Renal Disease in a Sample of Egyptian Populati · recruiting
- NCT05473299 — Xeltis Hemodialysis Access Graft: aXess Pivotal Study · NA · active not recruiting
- NCT05154773 — Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication · NA · active not recruiting
- NCT03994497 — Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Rena · NA · recruiting
Other Centre Hospitalier Universitaire de Nice trials
Trials by the same sponsor.
- NCT05897996 — Percutaneous Anastomosis Creation for Hemodialysis Access · NA · withdrawn
- NCT07499869 — INNOVATIVE BENEFITS OF A 4D VIRTUAL SIMULATOR · NA · not yet recruiting
- NCT07492251 — Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Ran · Phase 2 · not yet recruiting
- NCT07511608 — Development of a New Technique for Quantifying Mitochondrial DNA in Single Muscle Fibers · NA · not yet recruiting
- NCT07582406 — Codesign, Physical Activity, and Seniors · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02728817 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nice
- Last refreshed: 2 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02728817.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing